logo-loader

Predictive Oncology to raise $7.2M in multiple offerings

Last updated: 11:42 16 May 2022 EDT, First published: 11:35 16 May 2022 EDT

Moneybags changing hands
Predictive Oncology is a knowledge-driven company focused on applying artificial intelligence to develop optimal cancer therapies

Predictive Oncology Inc has entered into definitive agreements to sell shares and units with multiple institutional investors that are expected to generate gross proceeds of $7.2 million, the company announced.

In the first offering, the company will issue and sell more than 3.8 million shares at a price of $0.60 per share to several institutional investors for gross proceeds of $2.3 million. 

Predictive Oncology also agreed to issue up the same number of unregistered share purchase warrants exercisable at $0.70 per share to those investors. The warrants will become exercisable after six months and expire after five and a half years, the company said. 

READ: Predictive Oncology reports sharply higher consolidated revenue in 1Q 2022

In the second offering, the company agreed to issue and sell over 8.1 million shares of stock at a price of $0.60 per share to multiple institutional investors, for gross proceeds of $4.9 million. 

As part of the deal, more than 16.3 million warrants previously issued to those investors at exercise prices between $1 and $2 per share will be reduced to $0.70 per share. They will also become eligible after six months and expire after five and a half years. 

The company expects the offerings to occur on Wednesday. Net proceeds are expected to be used for working capital purposes.

Predictive Oncology is a knowledge-driven company focused on applying artificial intelligence to develop optimal cancer therapies, which can lead to more effective treatments and improved patient outcomes.

The Minnesota-based company uses a database of 150,000-plus cancer tumors, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of success.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

3 hours, 48 minutes ago